Study details
Enrolling now
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
Tiffany J. Braley, MD, MS
NCT IDNCT05269628ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
166
Study length
about 5.4 years
Ages
18–65
Locations
1 site in MI
About this study
This trial is testing whether cannabidiol (CBD), tetrahydrocannabinol (THC), or both, can improve sleep and reduce pain in people with multiple sclerosis (MS). The goal is to understand how CBD and/or THC may help with these conditions.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Cannabidiol (CBD)
- 2.Take Placebo CBD
- 3.Take Placebo THC
- +1 more
PhasePhase 2
DrugCBD
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
cannabinoid, cannabidiol, dronabinol
Drug routes
oral (Oral Solution)
Body systems
Neurology